List view / Grid view
Filter the results
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
See how a leading biochemistry company implemented Real-time Microbial Monitoring to streamline process control in their water system.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
Dave Williams explores why the cold chain requirements for COVID-19 vaccines may have a lasting impact on the pharmaceutical supply chain.